Elevated placental adenosine signaling contributes to the pathogenesis of preeclampsia

Takayuki Iriyama, Kaiqi Sun, Nicholas F. Parchim, Jessica Li, Cheng Zhao, Anren Song, Laura A. Hart, Sean C. Blackwell, Baha M. Sibai, Lee Nien L Chan, Teh Sheng Chan, M. John Hicks, Michael R. Blackburn, Rodney E. Kellems, Yang Xia

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Background: Preeclampsia is a prevalent hypertensive disorder of pregnancy and a leading cause of maternal and neonatal morbidity and mortality worldwide. This pathogenic condition is speculated to be caused by placental abnormalities that contribute to the maternal syndrome. However, the specific factors and signaling pathways that lead to impaired placentas and maternal disease development remain elusive. Methods and Results: Using 2 independent animal models of preeclampsia (genetically engineered pregnant mice with elevated adenosine exclusively in placentas and a pathogenic autoantibody-induced preeclampsia mouse model), we demonstrated that chronically elevated placental adenosine was sufficient to induce hallmark features of preeclampsia, including hypertension, proteinuria, small fetuses, and impaired placental vasculature. Genetic and pharmacological approaches revealed that elevated placental adenosine coupled with excessive A2B adenosine receptor (ADORA2B) signaling contributed to the development of these features of preeclampsia. Mechanistically, we provided both human and mouse evidence that elevated placental CD73 is a key enzyme causing increased placental adenosine, thereby contributing to preeclampsia. Conclusions: We determined that elevated placental adenosine signaling is a previously unrecognized pathogenic factor for preeclampsia. Moreover, our findings revealed the molecular basis underlying the elevation of placental adenosine and the detrimental role of excess placental adenosine in the pathophysiology of preeclampsia, and thereby, we highlight novel therapeutic targets.

Original languageEnglish (US)
Pages (from-to)730-741
Number of pages12
JournalCirculation
Volume131
Issue number8
DOIs
StatePublished - 2015

Fingerprint

Pre-Eclampsia
Adenosine
Mothers
Placenta Diseases
Adenosine A2B Receptors
Infant Mortality
Proteinuria
Autoantibodies
Placenta
Fetus
Animal Models
Pharmacology
Hypertension
Morbidity
Pregnancy
Enzymes

Keywords

  • Adenosine
  • Animal
  • Hypertension
  • Models
  • Preeclampsia
  • Pregnancy

ASJC Scopus subject areas

  • Physiology (medical)
  • Cardiology and Cardiovascular Medicine

Cite this

Iriyama, T., Sun, K., Parchim, N. F., Li, J., Zhao, C., Song, A., ... Xia, Y. (2015). Elevated placental adenosine signaling contributes to the pathogenesis of preeclampsia. Circulation, 131(8), 730-741. https://doi.org/10.1161/CIRCULATIONAHA.114.013740

Elevated placental adenosine signaling contributes to the pathogenesis of preeclampsia. / Iriyama, Takayuki; Sun, Kaiqi; Parchim, Nicholas F.; Li, Jessica; Zhao, Cheng; Song, Anren; Hart, Laura A.; Blackwell, Sean C.; Sibai, Baha M.; Chan, Lee Nien L; Chan, Teh Sheng; Hicks, M. John; Blackburn, Michael R.; Kellems, Rodney E.; Xia, Yang.

In: Circulation, Vol. 131, No. 8, 2015, p. 730-741.

Research output: Contribution to journalArticle

Iriyama, T, Sun, K, Parchim, NF, Li, J, Zhao, C, Song, A, Hart, LA, Blackwell, SC, Sibai, BM, Chan, LNL, Chan, TS, Hicks, MJ, Blackburn, MR, Kellems, RE & Xia, Y 2015, 'Elevated placental adenosine signaling contributes to the pathogenesis of preeclampsia', Circulation, vol. 131, no. 8, pp. 730-741. https://doi.org/10.1161/CIRCULATIONAHA.114.013740
Iriyama, Takayuki ; Sun, Kaiqi ; Parchim, Nicholas F. ; Li, Jessica ; Zhao, Cheng ; Song, Anren ; Hart, Laura A. ; Blackwell, Sean C. ; Sibai, Baha M. ; Chan, Lee Nien L ; Chan, Teh Sheng ; Hicks, M. John ; Blackburn, Michael R. ; Kellems, Rodney E. ; Xia, Yang. / Elevated placental adenosine signaling contributes to the pathogenesis of preeclampsia. In: Circulation. 2015 ; Vol. 131, No. 8. pp. 730-741.
@article{be3f986e77a54101bbb48adbe2f6bfba,
title = "Elevated placental adenosine signaling contributes to the pathogenesis of preeclampsia",
abstract = "Background: Preeclampsia is a prevalent hypertensive disorder of pregnancy and a leading cause of maternal and neonatal morbidity and mortality worldwide. This pathogenic condition is speculated to be caused by placental abnormalities that contribute to the maternal syndrome. However, the specific factors and signaling pathways that lead to impaired placentas and maternal disease development remain elusive. Methods and Results: Using 2 independent animal models of preeclampsia (genetically engineered pregnant mice with elevated adenosine exclusively in placentas and a pathogenic autoantibody-induced preeclampsia mouse model), we demonstrated that chronically elevated placental adenosine was sufficient to induce hallmark features of preeclampsia, including hypertension, proteinuria, small fetuses, and impaired placental vasculature. Genetic and pharmacological approaches revealed that elevated placental adenosine coupled with excessive A2B adenosine receptor (ADORA2B) signaling contributed to the development of these features of preeclampsia. Mechanistically, we provided both human and mouse evidence that elevated placental CD73 is a key enzyme causing increased placental adenosine, thereby contributing to preeclampsia. Conclusions: We determined that elevated placental adenosine signaling is a previously unrecognized pathogenic factor for preeclampsia. Moreover, our findings revealed the molecular basis underlying the elevation of placental adenosine and the detrimental role of excess placental adenosine in the pathophysiology of preeclampsia, and thereby, we highlight novel therapeutic targets.",
keywords = "Adenosine, Animal, Hypertension, Models, Preeclampsia, Pregnancy",
author = "Takayuki Iriyama and Kaiqi Sun and Parchim, {Nicholas F.} and Jessica Li and Cheng Zhao and Anren Song and Hart, {Laura A.} and Blackwell, {Sean C.} and Sibai, {Baha M.} and Chan, {Lee Nien L} and Chan, {Teh Sheng} and Hicks, {M. John} and Blackburn, {Michael R.} and Kellems, {Rodney E.} and Yang Xia",
year = "2015",
doi = "10.1161/CIRCULATIONAHA.114.013740",
language = "English (US)",
volume = "131",
pages = "730--741",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Elevated placental adenosine signaling contributes to the pathogenesis of preeclampsia

AU - Iriyama, Takayuki

AU - Sun, Kaiqi

AU - Parchim, Nicholas F.

AU - Li, Jessica

AU - Zhao, Cheng

AU - Song, Anren

AU - Hart, Laura A.

AU - Blackwell, Sean C.

AU - Sibai, Baha M.

AU - Chan, Lee Nien L

AU - Chan, Teh Sheng

AU - Hicks, M. John

AU - Blackburn, Michael R.

AU - Kellems, Rodney E.

AU - Xia, Yang

PY - 2015

Y1 - 2015

N2 - Background: Preeclampsia is a prevalent hypertensive disorder of pregnancy and a leading cause of maternal and neonatal morbidity and mortality worldwide. This pathogenic condition is speculated to be caused by placental abnormalities that contribute to the maternal syndrome. However, the specific factors and signaling pathways that lead to impaired placentas and maternal disease development remain elusive. Methods and Results: Using 2 independent animal models of preeclampsia (genetically engineered pregnant mice with elevated adenosine exclusively in placentas and a pathogenic autoantibody-induced preeclampsia mouse model), we demonstrated that chronically elevated placental adenosine was sufficient to induce hallmark features of preeclampsia, including hypertension, proteinuria, small fetuses, and impaired placental vasculature. Genetic and pharmacological approaches revealed that elevated placental adenosine coupled with excessive A2B adenosine receptor (ADORA2B) signaling contributed to the development of these features of preeclampsia. Mechanistically, we provided both human and mouse evidence that elevated placental CD73 is a key enzyme causing increased placental adenosine, thereby contributing to preeclampsia. Conclusions: We determined that elevated placental adenosine signaling is a previously unrecognized pathogenic factor for preeclampsia. Moreover, our findings revealed the molecular basis underlying the elevation of placental adenosine and the detrimental role of excess placental adenosine in the pathophysiology of preeclampsia, and thereby, we highlight novel therapeutic targets.

AB - Background: Preeclampsia is a prevalent hypertensive disorder of pregnancy and a leading cause of maternal and neonatal morbidity and mortality worldwide. This pathogenic condition is speculated to be caused by placental abnormalities that contribute to the maternal syndrome. However, the specific factors and signaling pathways that lead to impaired placentas and maternal disease development remain elusive. Methods and Results: Using 2 independent animal models of preeclampsia (genetically engineered pregnant mice with elevated adenosine exclusively in placentas and a pathogenic autoantibody-induced preeclampsia mouse model), we demonstrated that chronically elevated placental adenosine was sufficient to induce hallmark features of preeclampsia, including hypertension, proteinuria, small fetuses, and impaired placental vasculature. Genetic and pharmacological approaches revealed that elevated placental adenosine coupled with excessive A2B adenosine receptor (ADORA2B) signaling contributed to the development of these features of preeclampsia. Mechanistically, we provided both human and mouse evidence that elevated placental CD73 is a key enzyme causing increased placental adenosine, thereby contributing to preeclampsia. Conclusions: We determined that elevated placental adenosine signaling is a previously unrecognized pathogenic factor for preeclampsia. Moreover, our findings revealed the molecular basis underlying the elevation of placental adenosine and the detrimental role of excess placental adenosine in the pathophysiology of preeclampsia, and thereby, we highlight novel therapeutic targets.

KW - Adenosine

KW - Animal

KW - Hypertension

KW - Models

KW - Preeclampsia

KW - Pregnancy

UR - http://www.scopus.com/inward/record.url?scp=84923683461&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923683461&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.114.013740

DO - 10.1161/CIRCULATIONAHA.114.013740

M3 - Article

C2 - 25538227

AN - SCOPUS:84923683461

VL - 131

SP - 730

EP - 741

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 8

ER -